Suppr超能文献

通过高内涵成像进行多重分析以评估GPCR活性。

Multiplexed assays by high-content imaging for assessment of GPCR activity.

作者信息

Ross D A, Lee S, Reiser V, Xue J, Alves K, Vaidya S, Kreamer A, Mull R, Hudak E, Hare T, Detmers P A, Lingham R, Ferrer M, Strulovici B, Santini F

机构信息

Department of Automated Biotechnology, Merck & Co., North Wales, Pennsylvania 19454, USA.

出版信息

J Biomol Screen. 2008 Jul;13(6):449-55. doi: 10.1177/1087057108317685. Epub 2008 Jun 2.

Abstract

G-protein-coupled receptors (GPCR) participate in many disease pathways and represent the largest family of therapeutic targets. Thus, great investments are made to discover drugs modulating GPCR-mediated events. Among functional assays for screening GPCRs, the Transfluor imaging assay is based on redistribution of cytosolic beta-arrestin to an activated GPCR and has become widely used in high-content screening. However, assessing Transfluor alone has limitations: relying on a single mechanistic step of beta-arrestin redistribution during GPCR activation, providing no information on the stimulated GPCR's intracellular fate, and using only a single fluorescent color (green fluorescent protein). Taking full advantage of high-content imaging to screen approximately 2000 compounds, the authors multiplexed the Transfluor assay with an immunofluorescence-based quantification of GPCR internalization. This approach identified and classified 377 compounds interfering with agonist-induced activation of the Transfluor assay, receptor internalization, or both. In addition, a subset of compounds was analyzed for their performance across imaging, cell-based calcium release (fluorometric imaging plate reader [FLIPR]), and biochemical receptor binding assays (scintillation proximity assay). This indicated that the imaging assays have even better predictive power for direct inhibition of receptor binding than the FLIPR assay. In conclusion, compounds inducing unique responses can suggest novel mechanisms of action and be used as tools to study GPCR activation and internalization.

摘要

G蛋白偶联受体(GPCR)参与多种疾病途径,是最大的治疗靶点家族。因此,人们投入了大量资金来发现调节GPCR介导事件的药物。在用于筛选GPCR的功能测定中,转荧光成像测定基于胞质β-抑制蛋白向活化的GPCR的重新分布,已广泛应用于高内涵筛选。然而,单独评估转荧光有局限性:依赖于GPCR激活过程中β-抑制蛋白重新分布的单一机制步骤,不提供关于受刺激的GPCR细胞内命运的信息,并且仅使用单一荧光颜色(绿色荧光蛋白)。作者充分利用高内涵成像筛选约2000种化合物,将转荧光测定与基于免疫荧光的GPCR内化定量相结合。这种方法鉴定并分类了377种干扰激动剂诱导的转荧光测定激活、受体内化或两者的化合物。此外,分析了一组化合物在成像、基于细胞的钙释放(荧光成像板读数器[FLIPR])和生化受体结合测定(闪烁邻近测定)中的性能。这表明成像测定对受体结合的直接抑制具有比FLIPR测定更好的预测能力。总之,诱导独特反应的化合物可以提示新的作用机制,并用作研究GPCR激活和内化的工具。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验